+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sunitinib Malate Market - Global Forecast 2026-2032- Product Image
Sunitinib Malate Market - Global Forecast 2026-2032- Product Image
New

Sunitinib Malate Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 186 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6084048
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The sunitinib malate market is advancing as oncology stakeholders adapt to diagnostic progress, updated therapeutic pathways, and strengthened supply models. Senior decision-makers are responding to a landscape marked by heightened clinical demands and the necessity for resilient operational strategies.

Market Snapshot: Sunitinib Malate Market Size and Growth

The global sunitinib malate market is on a trajectory for robust expansion, projected to grow from USD 148.43 million in 2025 to USD 166.95 million in 2026, and reaching USD 322.01 million by 2032 at a compound annual growth rate (CAGR) of 11.69%. This growth reflects the product’s established role in targeted oncology therapies, its adoption across diverse regions, and strong sector investment in supply chain adaptability and optimized diagnostic accuracy.

Scope & Segmentation

This report provides a complete, actionable overview of the sunitinib malate market landscape to facilitate informed decisions. The segmentation ensures senior leaders can identify core opportunities and recognize operational bottlenecks within the following:

  • Indications: Gastrointestinal stromal tumor (GIST), pancreatic neuroendocrine tumor, renal cell carcinoma—each evaluated based on disease biology and molecular subtyping.
  • Treatment Lines: First-line, second-line, and third-line use case analysis incorporating evidence-based sequencing.
  • Care Settings: Hospitals and specialty clinics with inpatient and outpatient management protocols, including monitoring and adherence frameworks.
  • Distribution Channels: Hospital pharmacy, online pharmacy, and retail pharmacy, each assessed for logistics, dispensing approaches, and patient counseling models.
  • Regions: Americas, Europe, Middle East & Africa, Asia-Pacific—with each region analyzed for local regulatory pathways, reimbursement environments, and manufacturing trends.

Segmentation incorporates integrated technological adoption, such as digital health tools supporting outpatient management and advanced diagnostics that shape precision medicine strategies. Each segment analysis supports clearer forecasts and operational decisions.

Key Takeaways: Strategic Sunitinib Malate Market Insights

  • The oral administration of sunitinib malate supports flexible outpatient oncology care, reshaping how teams monitor adherence and deliver therapy outside hospital settings.
  • Molecular diagnostics and detailed patient stratification are increasingly integrated into clinical decision pathways, elevating precision in therapeutic selection.
  • Supply chain and procurement strategies now prioritize supplier diversity and robust demand planning in response to recent disruptions and market volatility.
  • Digital support tools and decentralized care models play a growing role in sustaining adherence and improving health outcomes for patients on oral oncology regimens.
  • Regional variations require nuanced approaches to access, influenced by differing regulatory frameworks and payer criteria across global markets.
  • Integrated investment in resilience, diagnostic infrastructure, and clinical education supports sustainable access and ongoing innovation throughout the value chain.

Tariff Impact: Supply Chain Rebalancing

Recent US tariff measures imposed on pharmaceutical ingredients and finished sunitinib forms in 2025 prompted strategic adjustment across the market. Leaders have re-examined sourcing, secured new procurement contracts, and invested in supplier redundancy and localized manufacturing capacity. Hospital pharmacies and distributors adapted inventory strategies, focusing on substantiating value in negotiations. Regulatory teams intensified efforts to validate suppliers and ensure ongoing quality, accelerating broader supply chain modernization and transparency initiatives.

Methodology & Data Sources

This market analysis uses a rigorous mixed-methods framework combining peer-reviewed clinical studies, regulatory and trial reviews, direct interviews with oncologists, pharmacists, and supply chain executives, and mapping of API and finished product flows. All insights are validated through cross-referenced data, with any regional data limitations clearly stated.

Why This Report Matters

  • Supports strategic planning through up-to-date segmentation and detailed operational intelligence, improving forecasting and investment outcomes.
  • Provides actionable levers for decision-makers to enhance supply resilience, integrate diagnostics, and expand patient access in evolving oncology settings.
  • Enables informed engagement with payers and regulators, promoting robust reimbursement models and improved patient outcomes.

Conclusion

Alignment between clinical innovation, resilient operations, and engaged stakeholder networks is pivotal for advancing therapeutic value in the sunitinib malate market. Organizations adopting integrated, forward-thinking strategies will be best positioned for ongoing growth and assured patient access.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Sunitinib Malate Market, by Indication
8.1. Gastrointestinal Stromal Tumor
8.1.1. Kit Mutant
8.1.2. Pdgra Mutant
8.1.3. Wild Type
8.2. Pancreatic Neuroendocrine Tumor
8.2.1. Functional
8.2.2. Non Functional
8.3. Renal Cell Carcinoma
8.3.1. Clear Cell Carcinoma
8.3.2. Non-Clear Cell Carcinoma
9. Sunitinib Malate Market, by Line Of Treatment
9.1. First Line
9.2. Second Line
9.3. Third Line
10. Sunitinib Malate Market, by End User
10.1. Hospital
10.2. Specialty Clinic
11. Sunitinib Malate Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Sunitinib Malate Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Sunitinib Malate Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Sunitinib Malate Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Sunitinib Malate Market
16. China Sunitinib Malate Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. Aark Pharmaceuticals
17.6. Active Biotech AB
17.7. Anant Pharmaceuticals Pvt. Ltd.
17.8. AstraZeneca PLC
17.9. Beijing Lunarsun Pharmaceutical Co., Ltd.
17.10. Bio-Techne Corporation
17.11. Brawn Laboratories Ltd.
17.12. Hetero Labs Limited
17.13. Hikma Pharmaceuticals PLC
17.14. JEIL PHARMACEUTICAL CO.,LTD.
17.15. Manus Aktteva Biopharma LLP
17.16. Medichem S.A.
17.17. Medzeel Lifescience
17.18. Nanjing First Pharmaceutical Co. Ltd,
17.19. Natco Pharma Limited
17.20. Pfizer Inc.
17.21. Sichuan Xieli Pharmaceutical Co., Ltd.
17.22. Synthland Limited
17.23. Taj Pharma India Limited
17.24. TargetMol Chemicals Inc.
17.25. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL SUNITINIB MALATE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL SUNITINIB MALATE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL SUNITINIB MALATE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL SUNITINIB MALATE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL SUNITINIB MALATE MARKET SIZE, BY KIT MUTANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL SUNITINIB MALATE MARKET SIZE, BY KIT MUTANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL SUNITINIB MALATE MARKET SIZE, BY KIT MUTANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PDGRA MUTANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PDGRA MUTANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PDGRA MUTANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL SUNITINIB MALATE MARKET SIZE, BY WILD TYPE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL SUNITINIB MALATE MARKET SIZE, BY WILD TYPE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL SUNITINIB MALATE MARKET SIZE, BY WILD TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FUNCTIONAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FUNCTIONAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FUNCTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON FUNCTIONAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON FUNCTIONAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON FUNCTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL SUNITINIB MALATE MARKET SIZE, BY CLEAR CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL SUNITINIB MALATE MARKET SIZE, BY CLEAR CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL SUNITINIB MALATE MARKET SIZE, BY CLEAR CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON-CLEAR CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON-CLEAR CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON-CLEAR CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL SUNITINIB MALATE MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL SUNITINIB MALATE MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL SUNITINIB MALATE MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL SUNITINIB MALATE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL SUNITINIB MALATE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL SUNITINIB MALATE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL SUNITINIB MALATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. AMERICAS SUNITINIB MALATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 65. AMERICAS SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 66. AMERICAS SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 67. AMERICAS SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 70. AMERICAS SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 74. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 96. EUROPE SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. EUROPE SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 98. EUROPE SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 99. EUROPE SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 100. EUROPE SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 101. EUROPE SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 102. EUROPE SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 103. EUROPE SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 106. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 112. AFRICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. AFRICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 114. AFRICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 115. AFRICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 116. AFRICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 117. AFRICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 118. AFRICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. AFRICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. ASEAN SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. ASEAN SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 131. ASEAN SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 132. ASEAN SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 133. ASEAN SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 134. ASEAN SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 135. ASEAN SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. ASEAN SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. GCC SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. GCC SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 139. GCC SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 140. GCC SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 141. GCC SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 142. GCC SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 143. GCC SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. GCC SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 153. BRICS SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. BRICS SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 155. BRICS SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 156. BRICS SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 157. BRICS SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 158. BRICS SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 159. BRICS SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. BRICS SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. G7 SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. G7 SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 163. G7 SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 164. G7 SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 165. G7 SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 166. G7 SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 167. G7 SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. G7 SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. NATO SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. NATO SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 171. NATO SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 172. NATO SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 173. NATO SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 174. NATO SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 175. NATO SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. NATO SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 177. GLOBAL SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. UNITED STATES SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 179. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 180. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 181. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 182. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 183. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 184. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. CHINA SUNITINIB MALATE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 187. CHINA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 188. CHINA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2032 (USD MILLION)
TABLE 189. CHINA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2032 (USD MILLION)
TABLE 190. CHINA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2032 (USD MILLION)
TABLE 191. CHINA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2032 (USD MILLION)
TABLE 192. CHINA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. CHINA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Sunitinib Malate market report include:
  • Aark Pharmaceuticals
  • Active Biotech AB
  • Anant Pharmaceuticals Pvt. Ltd.
  • AstraZeneca PLC
  • Beijing Lunarsun Pharmaceutical Co., Ltd.
  • Bio-Techne Corporation
  • Brawn Laboratories Ltd.
  • Hetero Labs Limited
  • Hikma Pharmaceuticals PLC
  • JEIL PHARMACEUTICAL CO.,LTD.
  • Manus Aktteva Biopharma LLP
  • Medichem S.A.
  • Medzeel Lifescience
  • Nanjing First Pharmaceutical Co. Ltd,
  • Natco Pharma Limited
  • Pfizer Inc.
  • Sichuan Xieli Pharmaceutical Co., Ltd.
  • Synthland Limited
  • Taj Pharma India Limited
  • TargetMol Chemicals Inc.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages186
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 166.95 Million
Forecasted Market Value ( USD ) by 2032 $ 322.01 Million
Compound Annual Growth Rate11.6%
Regions CoveredGlobal
No. of Companies Mentioned22

Related Topics

Related Reports

Sunitinib Malate - Global Strategic Business Report - Product Image

Sunitinib Malate - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Sunitinib Malate (CAS 341031-54-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Sunitinib Malate (CAS 341031-54-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Sunitinib Generics Market - Global Forecast 2025-2030 - Product Image

Sunitinib Generics Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Sunitinib (CAS 557795-19-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Sunitinib (CAS 557795-19-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Follicular Thyroid Cancer Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Follicular Thyroid Cancer Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Sunitinib Malate Market

Sunitinib malate, marketed under the brand name Sutent among others, falls within the category of targeted oncology drugs, specifically acting as a multi-targeted receptor tyrosine kinase (RTK) inhibitor. Its market presence is dictated by its efficacy in treating various types of cancer, including renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (PNETs). Sunitinib malate operates by blocking multiple molecular targets implicated in the growth, proliferation, and spread of cancer cells. Due to its targeted approach, it represents an alternative to conventional chemotherapy, offering a different side effect profile and method of action. Its utility in the field of oncology continues to be explored with ongoing research assessing its potential application in other malignancies. Several pharmaceutical and biotechnology companies have a stake in the market for sunitinib malate. Pfizer Inc. is the most prominent as the originator and manufacturer of Sutent, the landmark brand of sunitinib. Other companies may be involved in the distribution or production of generic forms of the drug. These include but are not limited to Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V. This market is subject to the stringent regulations and patent laws related to novel oncology therapies, which influence the competitive landscape as well as the availability of generic versions. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.